Computational design of disulfide cyclic peptide as potential inhibitor of complex NS2B-NS3 dengue virus protease

African Journal of Biotechnology

Volumn 10, Issue 57, 2011, Pages 12281-12290

  Tambunan, Usman Sumo Friend ^a   Apriyanti, Nissia ^a   Parikesit, Arli Aditya ^a   Chua, William ^a   Wuryani, Katarina ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Dengue virus (DENV); Molecular docking; Molecular dynamics; Serine protease NS2B and NS3

Indexed keywords

ARGINYLLYSYLARGININE; ASPARTIC ACID; CYCLOPEPTIDE; DISULFIDE CYCLOPEPTIDE; ENZYME INHIBITOR; LYSYLARGINYLLYSINE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DENGUE VIRUS; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN TARGETING; STANDARD; TEMPERATURE SENSITIVITY; VIRUS REPLICATION; VIRUS STRAIN;

DENGUE VIRUS;

EID: 80053355514     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Alonso H, Bliznyuk AA, Gready JE (2006). Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 26(5): 531-568
2. Brinkworth RI, Fairlie DP, Leung D, Young PR (1999). Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. J. Gen. Virol. 80(5): 1167-1177
3. Feher M, Williams CI (2009). Effect of input differences on the results of docking calculations. J. Chem. Infect. Model. 49(7): 1704-14
4. Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM (2009). Focus on flaviviruses: current and future drug targets. Future. Med. Chem. 1(2): 327.
5. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, Zhang GL, Marques ET, Tan TW, Brusic V, Salmon J, August JT (2008). Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS. Negl. Trop. Dis. 2(8): 272.
6. Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG (2008). Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from Dengue virus as a target. Antivir. Res. 80(2): 94-101.
7. Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG (2005). Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280(31): 28766-28774.
8. Manavalan B, Murugapiran SK, Lee G, Choi S (2010). Molecular modeling of the reductase domain to elucidate the reaction mechanism of reduction of peptidyl thioester into its corresponding alcohol in non-ribosomal peptide synthetases. BMC. Struct. Biol. 12(10): p. 1.
9. Tambunan USF, Alamudi S (2010). Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Bioinformation, 5(6): 250-254.
10. Tomlinson SM, Malmstrom RD, Watowich SJ (2009). New approaches to structure-based discovery of dengue protease inhibitors. Infect. Disord. Drug. Targets, 9(3): 327-343
11. Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, Vasudevan SG, Lescar J (2007). Crystal Structure of the Dengue Virus RNADependent RNA Polymerase Catalytic Domain at 1.85-Angstrom Resolution. Virol. J. 81(9): 4753-4765.
12. Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH (2005). Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 1; 16(1): 40-43.